business

This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.

Yahoo Finance · Jun 22, 2026, 1:41 PM · Also reported by 4 other sources

Definium Therapeutics (DFTX) stock skyrocketed Monday after the biotech company's psychedelics-based depression treatment scored a "best-case" win in final-phase testing. The company is testing an orally disintegrating tablet of lysergide, commonly known as LSD, in patients with major depressive disorder. In major depressive disorder, or MDD, those patients haven't responded to at least two prior depression treatments. Patients treated with…

Article preview — originally published by Yahoo Finance. Full story at the source.

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com PFG stock hits all-time high at 112.09 USD Investing.com Argan stock hits all-time high at 779.74 USD Investing.com Knowles Corp stock hits all-time high at 42.63 USD Investing.com Revolution Medicines stock hits all-time high at 166.64 USD

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

This Biotech's LSD-Based Drug Just Treated Depression. Now The Stock Is Sky-High.

Also covered by

More in business